Albireo enrolls first patient in phase 3 PFIC trial of A4250
Albireo Pharma announced the first patient has been enrolled in PEDFIC-1, a Phase 3 clinical trial of lead product candidate A4250, an ileal bile acid transporter inhibitor being studied for the treatment of patients with progressive familial intrahepatic cholestasis. May 16, 2018